colorectal cancer
Conditions
Interventions
XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8
Sponsors
Yokohama Rosai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histological confirmation of colorectal cancer 2.Unrecectable metastatic colorectal cancer 3.Metastatic colorectal cancer which has prior therapy of Oxliplatin-based chemotherapy with bevacizumab 4.Age over 20 5.Group(ECOG) Performance Status (PS) 0-1 6.An evaluable lesion is confirmed with objective documents such as CT,MRI within 4 weeks before registration 7.Satisfactory oral feeding 8. Have the treatment-free interval of 2-4 weeks since previous completion of treatment by a registration day 9.Vital organ functions are preserved within 2 weeks prior to entry 10.Life expectancy of more than 3 months 11. Written consent is taken
Exclusion criteria
Exclusion criteria: 1.History of severe allergy 2.Pregnant or lactating women or women of childbearing potential 3.Severe infection disease 4.HBsAg(+) or HBV-DNA(+) 5.Previous history of hemoptysis or evidence of bleeding diathesis or coagulopathy 6. Metastases to the CNS 7. Complication of inflammation or active gastrointestinal 8. Non-healing wound 9. anti-platelets therapy 10. History of thrombosis or cerebrovascular disorder 11. Uncontrolled high blood pressure 12. Serious heart disease 13. Uncontrolled diarrhea 14.Paresis of intestine or intestinal obstruction 15.Interstitial pneumonitis 16.Serious peritoneal fluid and pericardial fluid 17.Multiple primary cancer which heals within five years 18. receiving atazanavir sulfate 19. requiring steroid drug 20.Have the homo and double heterozygote of *6,*28. 21. Other conditions not suitable for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival | — |
Countries
Japan
Outcome results
None listed